Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves aim to boost brain function in memory loss

NCT ID NCT07691918

Symptom relief Sponsor: Virginia Polytechnic Institute and State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study tests whether low-intensity focused ultrasound (LIFU) is safe and tolerable for people with mild cognitive impairment (MCI), a condition that can lead to dementia. Participants receive either real or sham ultrasound to the brain. Researchers monitor side effects and measure changes in memory and thinking using standard cognitive tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-intensity focused ultrasound (LIFU)
What this could lead to
If safe and effective, this could point toward a non-invasive way to slow cognitive decline in people with mild cognitive impairment.
What could go wrong
This is an early, small study focused on safety, not proof of benefit. The treatment may have no effect on cognition, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Montreal Cognitive Assessment (MoCA) scores between 18-23 inclusive, and able to consent to their own medical care. Exclusion Criteria: * Claustrophobia * MRI contraindications (pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, or other implants) * CT contraindications (pregnancy) * Non-AD etiology (eg. Lewy body disease, vascular dementia, alcohol/drug related damage) * Taking anti-amyloid antibodies * Neuromod within 6 months of the study * History of other neurological disorder * Hx of head injury with LOC \> 10 min * Active alcohol or drug dependence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mild cognitive impairment (MCI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mild cognitive impairment (MCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fralin Biomedical Research Institute at VTC

    Roanoke, Virginia, 24016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.